3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gynecologic
4
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
36
Carboplatin
28
Paclitaxel
23
Filgrastim
17
Nivolumab
14
Gemcitabine
14
Cyclophosphamide
14
Ifosfamide
13
Cisplatin
13
Docetaxel
12
Specimen Handling
11
Etoposide
11
olaparib
9
Peripheral Blood Stem Cell Transplantation
9
Magnetic Resonance Spectroscopy
8
fludarabine
6
Temozolomide
6
Ipilimumab
6
Fluorouracil
6
Biopsy
6
Albumin-Bound Paclitaxel
6
rucaparib
5
avelumab
5
atezolizumab
5
Trastuzumab
5
Thiotepa
5
Taxes
5
Standard of Care
5
palbociclib
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
trastuzumab deruxtecan
×
Genitourinary
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled